Esranur Aydın (Esranur Aydin)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 9

Top Topics

Inferior Vena Cava

Top Venues

Therapeutic advances in medical oncology

JCO precision oncology

Molecules (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Esranur Aydın, Unal Metin Tokat, Eylül Özgü, Ashkan Adibi, Onur Tutar, Razelle Kurzrock, Mutlu Demiray
Navigating uncharted territory: a case report and literature review on the remarkable response to personalized crizotinib containing combinational therapy in a pazopanib refractory patient with novel alterations. Therapeutic advances in medical oncology 16 (2024)
Esranur Aydın, Unal Metin Tokat, Eylül Özgü, Ashkan Adibi, Onur Tutar, Razelle Kurzrock, Mutlu Demiray
Navigating uncharted territory: a case report and literature review on the remarkable response to personalized crizotinib containing combinational therapy in a pazopanib refractory patient with novel alterations. Therapeutic advances in medical oncology 16 (2024)
Esranur Aydın, Unal Metin Tokat, Eylül Özgü, Ashkan Adibi, Onur Tutar, Razelle Kurzrock, Mutlu Demiray
Navigating uncharted territory: a case report and literature review on the remarkable response to personalized crizotinib containing combinational therapy in a pazopanib refractory patient with novel alterations. Therapeutic advances in medical oncology 16 (2024)
Eylül Özgü, Esranur Aydın, Ashkan Adibi, Ünal Metin Tokat, Onur Tutar, Jiancheng Hu, Irem Demiray, Razelle Kurzrock, Mutlu Demiray
Exceptional Response to MEK Inhibition in a Patient With RAF1-Mutant Myxofibrosarcoma: Case Report and Mechanistic Overview. JCO precision oncology 7 (2023)
Ashkan Adibi, Unal Metin Tokat, Eylül Özgü, Esranur Aydın, İrem Demiray, Mutlu Demiray
PARP inhibitor combinations with high-dose vitamin C in the treatment of Ewing sarcoma: two case reports and mechanistic overview. Therapeutic advances in medical oncology 15 (2023)
Eylül Özgü, Esranur Aydın, Ashkan Adibi, Ünal Metin Tokat, Onur Tutar, Jiancheng Hu, Irem Demiray, Razelle Kurzrock, Mutlu Demiray
Exceptional Response to MEK Inhibition in a Patient With RAF1-Mutant Myxofibrosarcoma: Case Report and Mechanistic Overview. JCO precision oncology 7 (2023)
Eylül Özgü, Esranur Aydın, Ashkan Adibi, Ünal Metin Tokat, Onur Tutar, Jiancheng Hu, Irem Demiray, Razelle Kurzrock, Mutlu Demiray
Exceptional Response to MEK Inhibition in a Patient With RAF1-Mutant Myxofibrosarcoma: Case Report and Mechanistic Overview. JCO precision oncology 7 (2023)
Ashkan Adibi, Unal Metin Tokat, Eylül Özgü, Esranur Aydın, İrem Demiray, Mutlu Demiray
PARP inhibitor combinations with high-dose vitamin C in the treatment of Ewing sarcoma: two case reports and mechanistic overview. Therapeutic advances in medical oncology 15 (2023)
Esranur Aydın, Ahmet Mesut Şentürk, Hatice Başpınar Küçük, Mustafa Güzel
Cytotoxic Activity and Docking Studies of 2-arenoxybenzaldehyde N-acyl Hydrazone and 1,3,4-Oxadiazole Derivatives against Various Cancer Cell Lines. Molecules (Basel, Switzerland) 27 (21) (2022)